济南治早泄治疗(济南射精无力可以调理好吗) (今日更新中)

ATHENS, Jan. 20 (Xinhua) - A seven- month- old Libyan baby died in an Athens Children's hospital on Friday in the first fatality linked to the H1N1 flu virus of the new year in Greece, local authorities reported.According to local media reports citing Greek doctors who treated the boy, he had been infected with the virus in Libya, where he was diagnosed with common flu and received insufficient therapy, before transferred to Greece.An Ukrainian woman who is being treated in another Greek hospital for pneumonia is the second severe case of the swine flu to be reported in the country this season.Last year deaths caused by the H1N1 virus in Greece climbed exceeded the 100 victims and many more patients were treated for complications caused by the virus which first emerged in 2009 in Asia and developed into a worldwide pandemic.Greek Centre for Disease Control and Prevention (KEELPNO) experts noted that Greece does not face a high risk so far this year, but suggested to people of vulnerable groups that reach up to 1.5 million persons in Greece, to get vaccinated.Last year's high number of fatalities was attributed to the fact that several people who should have been vaccinated, skimped vaccination which is not obligatory.

BAIKONUR, Kazakhstan, Nov. 9 (Xinhua) -- Russia's Phobos-Grunt probe and China's Yinghuo-1 satellite were launched from the Baikonur cosmodrome in Kazakhstan on a Zenit-2SB rocket at 00:16 am Moscow time Wednesday (2016 GMT Tuesday).The main aim of the Phobos-Grunt unmanned mission is to bring back the first ever soil sample from Phobos, the larger of Mars' two moons.Russia had spent about 5 billion rubles (about 161 million U.S. dollars) preparing for the three-year mission, which would include drilling Phobos' surface and returning 200 grams of soil back to Earth, according to Russian state space agency Roscosmos.The mission would also collect bacteria samples for two Russian and one U.S. biological experiments.In the meantime, China's first Mars probe Yinghuo will go into orbit around Mars and observe the planet itself.Phobos-Grunt is planned to reach Mars in 2012, then deploy its lander for Phobos in 2013 and return the soil sample back to Earth in August 2014.The Chinese probe, which would not land on Mars nor return to the Earth, is expected stay permanently in the space and communicate with the ground control directly via satellites.The Chinese probe is 75 cm long, 75 cm wide and 60 cm high. It weighs 115 kilograms and was designed for a two-year life to discover why water disappeared from Mars and shed light on other environmental changes on the planet.Victor Khartov, chief designer and director general of Lavochkin Research & Production Association, told Xinhua that the three-year mission is highly complicated."It consists of eight sub-missions: launch, travel to Mars vicinities, separation with the Chinese probe YH-1, landing on Phobos, soil collection, launch from Phobos, way back to the Earth, and final landing. Failure of any one of them could doom the entire project," he said.The launch of Phobos-Grunt and Yinghuo-1, originally scheduled for October 2009 on a Russian carrier rocket, has been postponed until 2011 due to "technical reasons" on the Russian side.

WASHINGTON, Dec. 21 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Wednesday approved Isentress for the treatment of HIV-1 infection for children and adolescents.The drug is part of a class of medications called HIV integrase strand transfer inhibitors that works by slowing the spread of HIV in the body. It was first approved for use in adult patients in October 2007, under FDA's accelerated approval program."Many young children and adolescents are living with HIV and this approval provides an important additional option for their treatment," said Edward Cox, director of the Office of Antimicrobial Products in the FDA's Center for Drug Evaluation and Research.Isentress is a pill that can be taken twice daily, with or without food. The pill is also available in a chewable form. As the two tablet formulations are not interchangeable, the chewable form is only approved for use in children ages 2 to 11.A single, multi-center clinical trial of 96 children and adolescents aged 2-18 years with HIV-1 infection evaluated the safety and effectiveness of Isentress. These patients previously received treatment for HIV-1 infection. After 24 weeks of treatment with Isentress, 53 percent of these patients had an undetectable amount of HIV in their blood.According to the FDA, the most commonly reported severe, treatment-related side effects in patients taking Isentress include trouble sleeping and headache. The frequency of these side effects is similar for children and adults. One pediatric patient reported severe treatment-related insomnia, while another pediatric patient experienced a drug-related skin rash.

BEIJING, Oct. 27 (Xinhuanet) -- Virginia M. Rometty, 54, will succeed present IBM CEO Sam Palmisano to be the next chief executive at the start of 2012, the company announced Tuesday.This is unprecedented in the New York-based company's 100-year history, because Rometty, a senior vice president of IBM, will be its first female CEO.Since joining the company three decades ago, Ms. Rometty has contributed a lot to the giant I.T. Company.After graduating from Northwestern University with an undergraduate degree in computer science, she entered the company in 1981 as a systems engineer. In virtue of outstanding performance, she was quickly promoted to management.For the following 20 years, she worked with clients in banking, insurance, and telecommunications, to name a few.In 2002, Rometty caught Palmisano's attention when she helped integrate the 3.5 billion dollar acquisition of the big business consulting firm PricewaterhouseCoopers Consulting, IBM's largest deal ever at the time.Then she became senior vice president of the group and group executive for sales, marketing and strategy in 2009. Under her leading, the business in overseas emerging markets including China, India, Brazil and several African nations, has increased sharply.New York Times reported that such markets now accounted for 23 percent of IBM.’s revenue, up from 20 percent when she took over.“Ginni got it because she deserved it,” Mr. Palmisano told the New York Times. "Ginni" is an informal first name used by her friends and colleagues.The selection of Rometty for chief executive will make her the 17th female CEO in the Fortune 500 on the following January. Other prominent women who play the same role as Rometty include Indra Nooyi of PepsiCo, Ellen J. Kullman of DuPont, Meg Whitman of Hewlett-Packard, and so on.

来源：资阳报